Topics Access and Benefit-Sharing An EU Biodiversity Market by 2027? The new EU’s Roadmap towards Nature CreditsChina’s Draft Environmental Code: Access and Benefit-Sharing for Chinese Non-Human Biological Resources – What Life Sciences Companies Should Know Africa EU Talking Life Sciences Audiocast: Regulatory and Policy Developments from South Africa - SAHPRA's Proposed Black Economic Empowerment (BEE) PolicyEU Talking Life Sciences Audiocast: Developments in the African Medicines Agency and Regulatory Convergence Anti-Corruption Germany Headed to Stricter Criminal Laws Against “Corruption In The Healthcare Sector”Deferred Prosecution Agreements in the UK: One Step Closer to the Introduction of a New Enforcement Tool in Bribery and Corruption Cases Artificial Intelligence (AI) MHRA Outlines New Strategic Approach to Artificial IntelligenceWHO Publishes Regulatory Considerations on AI for Health Brexit Are you Windsor Framework ready? A focus on pharmaceutical supply chains and promotional materialEuropean Commission Proposes to Extend Transitional Periods for In-Vitro-Diagnostic Medical Devices CE Mark UK's Medical Device Post-market Surveillance Statutory Instrument Laid Before Parliament – What are the Key Changes for Medical Device Regulation?UK MHRA Announces Intention To Recognize Certain International Approvals For Certain Medical Devices China China’s Draft Environmental Code: Access and Benefit-Sharing for Chinese Non-Human Biological Resources – What Life Sciences Companies Should Know Clinical Trial Applications Germany will revise laws for clinical trials with pharmaceuticals, medical devices and companion diagnostics – Overview of the “Medical Research Act”EMA Releases Reflection Paper on AI/ML in the Medicinal Product Lifecycle Commercial Structures EU Talking Life Sciences Audiocast: Episode 4 – EU and UK Pharmaceutical Regulation of Tax Structures and Financial Flows - Implications for Global Supply Chains Compassionate Use New Early Access and Off-Label Use Rules in FranceBelgium Amends Compassionate Use and Medical Need Program Rules to Expand Access Competition European Commission Publishes Exceptional Antitrust Guidance for Undertakings Collaborating to Address the Shortage of Essential Products and Services during COVID-19DEFRA announces raft of new measures to support food supply and key workers in response to COVID-19 Conformity Assessment UK Government to Recognize CE Marks Indefinitely (other than for Medical Devices and IVDs) Corporate The CDA - Five Practical ConsiderationsThe Unintended Consequences of Non-Disclosure Agreements Corporate Reporting and Disclosures Green Groceries: Key ESG Issues for the FMCG Industry (including FBOs) Cosmetics The Cali Fund and Why Legal Certainty Matters for Life Sciences R&DJust Weeks After COP16: CBD Secretariat Launches Stakeholder Consultations for the Operationalization of the DSI Mechanism. How Should Companies Engage? COVID19 What Companies Should Know About the WHO Pandemic AgreementEU Health Emergency Mechanisms: Impact on Medical Devices Employment European Regulators Set Out Data Anonymization StandardsNew Directors’ Remuneration Regime: The Facts for Life Sciences Companies Environmental & Clean Technology New EU Wastewater Treatment Fees on Producers of Pharmaceutical and Cosmetic ProductsHistoric Marine Biodiversity Treaty creates new Access and Benefit-Sharing obligations for life sciences companies Environmental, Social and Governance (ESG) An EU Biodiversity Market by 2027? The new EU’s Roadmap towards Nature CreditsThe EPR Obligations of the New Urban Wastewater Treatment Directive: Key Questions and Next Steps for Member States EU Pharma Law Revision European Parliament adopts its Position on EU Pharma Law Review: 8 Key Takeaways for IndustryEU Pharma Legislation Review Series: Unitary Supplementary Protection Certificates and Recast EU State aid rules German Exemptions from Mandatory Rebates for Pharma Companies Are in Line with EU State Aid Rules European Union An EU Biodiversity Market by 2027? The new EU’s Roadmap towards Nature CreditsEuropean Health Data Space Published Export UK Government to Recognize CE Marks Indefinitely (other than for Medical Devices and IVDs)The Implications of the Windsor Framework Extended Producer Responsibility The EPR Obligations of the New Urban Wastewater Treatment Directive: Key Questions and Next Steps for Member StatesNew EU Wastewater Treatment Fees on Producers of Pharmaceutical and Cosmetic Products Financial Synthetic Royalty and Drug Development Financings – A Funding Structure Growing in EuropeNon-Dilutive Financing: The U.S. Trend Catching on in Europe’s Life Sciences Sector Food & Beverage EU Court Overturns EU-wide Botanical Food BanFood Standard Agencies in Great Britain unlawfully classified monk fruit as novel, High Court rules Food & Drug Regulatory What Companies Should Know About the WHO Pandemic AgreementEU Joint Procurement – An Overview Food Labelling UK Judge Permits “Raw” Label for Honey Gene Editing EU Pharma Legislation Review Series: GMO MedicinesEU Pharma Legislation Review Series: Addressing Environmental Risks Global Supply Chain Historic Marine Biodiversity Treaty creates new Access and Benefit-Sharing obligations for life sciences companiesEU Pharma Legislation Review Series: Decentralized Manufacturing GMOs EU Pharma Legislation Review Series: GMO Medicines Greenwashing EU Adopts New Rules on Greenwashing and Social Impact ClaimsEU Pharma Legislation Review Series: Addressing Environmental Risks HEALTH PRIVACY European Health Data Space PublishedEuropean Commission Publishes Action Plan on Cybersecurity of Hospitals and Healthcare Providers Healthcare system The Updated NHS Commercial Framework for New MedicinesEuropean Commission Publishes Action Plan on Cybersecurity of Hospitals and Healthcare Providers Intellectual Property What Companies Should Know About the WHO Pandemic AgreementUK HRA Consults on a New Model Investigator-Initiated Study Agreement Legal Title EU Talking Life Sciences Audiocast: Episode 4 – EU and UK Pharmaceutical Regulation of Tax Structures and Financial Flows - Implications for Global Supply Chains Life Sciences An EU Biodiversity Market by 2027? The new EU’s Roadmap towards Nature CreditsSynthetic Royalty and Drug Development Financings – A Funding Structure Growing in Europe M&A EU Talking Life Sciences Audiocast: Current Trends in M&A and Licensing in the Life Sciences Industry Marketing authorisation Are you Windsor Framework ready? A focus on pharmaceutical supply chains and promotional materialEuropean Court of Justice requested to clarify the scope of the market exclusivity right for orphan drugs – German courts remain divided Medical Devices EU Joint Procurement – An OverviewThe Covington European Life Sciences Symposium 2025 Medical Devices What Companies Should Know About the WHO Pandemic AgreementEU Joint Procurement – An Overview Medicinal Products What Companies Should Know About the WHO Pandemic AgreementEU Joint Procurement – An Overview Medicinal Products EU Joint Procurement – An OverviewThe Updated NHS Commercial Framework for New Medicines Miscellaneous UK Government Announces Launch of Pilot Scheme to Accelerate Access to Innovative Medical DevicesUK PMCPA Publishes First Ever Guidance to Pharmaceutical Companies about Social Media Novel Food Food Standard Agencies in Great Britain unlawfully classified monk fruit as novel, High Court rules Patents Single Market Emergency Instrument: Potential Impact on Medical DevicesEU Talking Life Sciences Audiocast: Supplementary Protection Certificates – What It Means for a Product to Be Protected by a Basic Patent in Force and Future Proposals in the EU Pharma Re-Launch of UK’s Innovative Licensing and Access Pathway (“ILAP”)European Commission Consults on Update to Pharmacovigilance Rules Pharmaceutical Advertising and Communications European Court of Justice requested to clarify the scope of the market exclusivity right for orphan drugs – German courts remain dividedNew ABPI Code and PMCPA Constitution and Procedure Published Pharmaceutical companies What Companies Should Know About the WHO Pandemic AgreementThe Cali Fund and Why Legal Certainty Matters for Life Sciences R&D Pharmaceutical Rules European Commission Consults on Update to Pharmacovigilance RulesEuropean Court of Justice requested to clarify the scope of the market exclusivity right for orphan drugs – German courts remain divided Privacy & Data Security European Commission Publishes Action Plan on Cybersecurity of Hospitals and Healthcare ProvidersGermany enacts stricter requirements for the processing of Health Data using Cloud-Computing – with potential side effects for Medical Research with Pharmaceuticals and Medical Devices social media EU Talking Life Sciences Audiocast: Episode 3 – Social Media Challenges for Pharma Companies - Comparing Approaches in Europe and the USUK PMCPA Publishes First Ever Guidance to Pharmaceutical Companies about Social Media Supply Chain Due Diligence Green Groceries: Key ESG Issues for the FMCG Industry (including FBOs) Tax EU Talking Life Sciences Audiocast: Episode 4 – EU and UK Pharmaceutical Regulation of Tax Structures and Financial Flows - Implications for Global Supply Chains Tax Structures EU Talking Life Sciences Audiocast: Episode 4 – EU and UK Pharmaceutical Regulation of Tax Structures and Financial Flows - Implications for Global Supply Chains UKCA Mark MHRA Consults on New UK Pre-Market Medical Device MeasuresUK's Medical Device Post-market Surveillance Statutory Instrument Laid Before Parliament – What are the Key Changes for Medical Device Regulation? Uncategorized Germany enacts stricter requirements for the processing of Health Data using Cloud-Computing – with potential side effects for Medical Research with Pharmaceuticals and Medical DevicesNew EU Wastewater Treatment Fees on Producers of Pharmaceutical and Cosmetic Products
